Sign in

CIK 0001601485

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Elicio Therapeutics, Inc.

Sign in to watch
Ticker
ELTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
113430072
Phone
+1 857-209-0050
Business address
451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
Former names
Angion Biomedica Corp.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-08-31 Chudnovsky Yekaterina Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 Ashe Carol Gail Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 Nissenson Allen Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 Venkatesan Jay Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 WILSON KAREN J Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 ADAMS JULIAN Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-08-31 RUFFOLO ROBERT R Director Grant or award · Stock Option (Right to Buy) +21,750 21,750
2026-07-16 DeMuth Peter Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +52,832 52,832
2026-07-16 Connelly Robert CEO, President and Director Grant or award · Stock Option (Right to Buy) +186,944 186,944
2026-07-16 Shah Preetam Grant or award · Stock Option (Right to Buy) +60,833 60,833
2026-07-16 Haqq Christopher Grant or award · Stock Option (Right to Buy) +64,643 64,643
2026-02-02 Connelly Robert CEO, President and Director Grant or award +73,600 120,570
2026-02-02 Connelly Robert CEO, President and Director Grant or award · Stock Option (Right to Buy) +147,200 147,200
2026-02-02 Shah Preetam Grant or award +24,000 24,000
2026-02-02 Shah Preetam Grant or award · Stock Option (Right to Buy) +47,900 47,900
2026-02-02 DeMuth Peter Chief Scientific Officer Grant or award +20,800 21,543
2026-02-02 DeMuth Peter Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +41,600 41,600
2026-02-02 Haqq Christopher Grant or award +25,400 57,381
2026-02-02 Haqq Christopher Grant or award · Stock Option (Right to Buy) +50,900 50,900
2025-12-09 DeMuth Peter Chief Scientific Officer Exercise or conversion +362 $4.41 $2K 743

Page 1 of 9 · 171 trades